Bard PowerPort catheter lawsuit MDL 3081: where the litigation actually stands as bellwether trials begin

The Bard PowerPort litigation has moved from procedural development to active bellwether trials. MDL 3081 (In re: Bard Implanted Port Catheter Products Liability Litigation), centralized in the U.S. District Court for the District of Arizona before Judge David G. Campbell, consolidates approximately 3,044 federal cases as of April 2026 — a substantial increase from approximately 1,300 cases at end of 2024. Judge Campbell previously presided over the Bard IVC filter MDL (peaked at 8,000+ claims, settled in stages) and brings substantial mass tort experience to the PowerPort litigation. The defendants are C.R. Bard, Inc. and parent company Becton, Dickinson and Company (BD).

Two recent procedural developments substantially affect the litigation's trajectory. On March 5, 2026, Judge Campbell denied nearly all of Bard's summary judgment motions — a significant win for plaintiffs heading into bellwether trials. The denial preserved plaintiffs' design defect claims, failure-to-warn theories, and most other substantive case theories. On April 21, 2026, the first bellwether trial began — Cook v. Becton Dickinson, an infection case where the catheter allegedly failed within a month of implantation. Five more bellwether trials are scheduled through early 2027, covering different injury types across the various PowerPort product lines (polyurethane, Groshong, and silicone devices).

The substantive theory in the litigation focuses on material defects in the catheter components. Plaintiffs allege the polyurethane and barium sulfate material composition causes catheters to fracture and migrate inside patients. A key procedural issue is Bard's reliance on the FDA 510(k) clearance process, which allowed PowerPort to enter the market in 1999 without clinical testing for long-term safety or durability. Plaintiffs argue that 510(k) clearance doesn't immunize manufacturers from product liability claims when the cleared product proves defective in clinical use. The PowerPort devices have been subject to prior FDA recalls — including the PowerPort duo M.R.I. recall on March 25, 2021 (catheter component issues) and a PowerPort devices recall on October 1, 2019 (component mismatch concerns) — supporting plaintiffs' theory that Bard had material knowledge of problems before the litigation.

This is the science behind the catheter fracture theory, the procedural history of MDL 3081 through the current bellwether phase, the eligibility framework for current and prospective plaintiffs, the settlement projections based on bellwether outcomes, and the strategic considerations for affected patients navigating the substantial documentation requirements.

What PowerPort catheters are and the alleged defect

Implanted port catheters provide long-term vascular access:

Device purpose. PowerPort and similar implanted port catheters serve as long-term intravenous access points for:

• Chemotherapy delivery to cancer patients
• Long-term antibiotic therapy
• Total parenteral nutrition (TPN)
• Frequent blood draws or IV medication administration
• Other situations requiring sustained vascular access

The devices are surgically implanted under the skin (typically in the chest wall) with a catheter threaded into a large vein. Medical professionals access the port through needle punctures rather than repeated peripheral IV sticks.

Material composition issue. PowerPort catheters use polyurethane material mixed with barium sulfate (which makes the catheter visible on imaging). Plaintiffs allege:

• The polyurethane-barium sulfate composition is structurally unstable
• The material degrades when exposed to chemotherapy drugs and other infusions
• Microscopic cracks develop over time
• The cracks propagate into fractures
• Fractures release fragments that migrate through the vascular system

Specific products implicated. The MDL covers multiple Bard port catheter product lines:

• PowerPort (standard polyurethane)
• PowerPort duo M.R.I.
• Groshong devices
• Silicone devices
• Various older Bard port catheter products

Internal corporate knowledge. Discovery in MDL 3081 has produced internal Bard documents about the polyurethane-barium sulfate composition issues. The 2019 and 2021 FDA recalls support plaintiffs' theory that Bard had information about device problems before initiating the recalls.

The alleged injuries

Plaintiffs in MDL 3081 allege various injuries:

Catheter fracture. The catheter portion breaks while inside the body. Fractures can occur:

• During normal use (chemotherapy infusion, flushing)
• During access procedures
• Spontaneously after extended use
• During device removal

Fragment migration. Broken catheter pieces migrate through the vascular system to:

• Heart chambers
• Pulmonary arteries (potentially causing pulmonary embolism)
• Other distant vascular sites
• Requires surgical retrieval

Bloodstream infections (sepsis). Bacterial infection of the catheter:

• Difficult to treat with antibiotics alone
• Often requires device removal
• Can progress to systemic sepsis
• Potentially life-threatening

Deep vein thrombosis (DVT). Blood clot formation related to catheter presence:

• Local thrombosis at catheter site
• Potential for embolic complications
• Treatment with anticoagulation required

Vascular injury and laceration. Physical damage to blood vessels:

• During implantation
• During use due to device defects
• During fragment migration
• May require vascular surgery

Need for surgical removal. Damaged or infected devices often require:

• Removal of original device
• Replacement with alternative access method
• Sometimes complicated extraction due to fibrin encapsulation
• Vascular surgery for migrated fragments

Population especially affected. Cancer patients comprise the largest plaintiff population. The devices were specifically used for chemotherapy delivery, exposing patients with already compromised health to additional medical complications from device failure. Some plaintiffs died during the litigation — including second bellwether plaintiff Wanda Miller, who died February 2, 2026, before her scheduled July 7 trial date.

The procedural history of MDL 3081

The litigation has developed:

Pre-2023. Federal PowerPort lawsuits filed across various district courts. Plaintiffs' attorneys recognized common factual and legal issues.

August 8, 2023. Judicial Panel on Multidistrict Litigation issued transfer order consolidating cases. MDL 3081 established in District of Arizona before Judge David G. Campbell.

2024. Active discovery and case management. Substantial document production from Bard. Plaintiff Fact Sheet (PFS) framework established covering 8 key areas: personal/claim background, medical history, health insurance, previous claims, witness information, document identification, and document requests.

Throughout 2025. Case count grew from approximately 1,300 to over 2,500 by year-end. More than 1,000 new cases filed in 2025 alone — more than doubling the case count from 2024.

December 2, 2025. Bellwether trial schedule established. Six trials scheduled May 2026 through February 2027.

January 2026. Federal court preparations for bellwether trials continued. Discovery disputes resolved. Expert testimony rulings issued.

February 2, 2026. Second bellwether plaintiff Wanda Miller died. Her July 7, 2026 trial date was placed under review.

March 5, 2026. Judge Campbell denied nearly all of Bard's summary judgment motions — significant procedural win for plaintiffs.

April 21, 2026. FIRST BELLWETHER TRIAL BEGAN. Cook v. Becton Dickinson — an infection case where catheter allegedly failed within a month of implantation.

Additional bellwether schedule:

• Second bellwether: July 7, 2026 (under review due to plaintiff death)
• Third bellwether: October 13, 2026
• Fourth bellwether: December 1, 2026
• Fifth bellwether: February 2, 2027
• Sixth bellwether: additional 2027 date

The six bellwether cases collectively cover:

• 3 infection cases
• 2 thrombus cases
• 1 fracture case
• Across polyurethane, Groshong, and silicone devices

The diversity reflects the court's intent to test liability theories across distinct failure modes rather than concentrating on a single injury profile.

The 510(k) clearance defense

A central procedural issue is Bard's reliance on FDA 510(k) clearance:

510(k) clearance process. Under 21 U.S.C. §360(k) and FDA regulations, medical devices can be cleared for market through demonstration of "substantial equivalence" to existing devices rather than full safety testing through premarket approval (PMA) process. The 510(k) process:

• Faster than PMA
• Less expensive for manufacturers
• Doesn't require clinical testing for safety
• Doesn't establish long-term durability
• Used for devices considered similar to existing market products

PowerPort 510(k) history. PowerPort received FDA 510(k) clearance in 1999 without clinical testing for long-term safety or durability. Bard argued in summary judgment motions that 510(k) clearance preempts state product liability claims and immunizes the company from liability.

Plaintiffs' counter-arguments. Plaintiffs argued:

• 510(k) clearance doesn't establish device safety
• The U.S. Supreme Court has held in Medtronic v. Lohr that 510(k) clearance doesn't preempt state product liability claims (the PMA process can preempt under Riegel v. Medtronic, but 510(k) doesn't have the same effect)
• Bard prioritized market speed over patient safety
• The 510(k) framework doesn't establish that PowerPort is actually safe

Judge Campbell's denial of summary judgment. The March 2026 ruling preserved plaintiffs' claims, accepting that 510(k) clearance doesn't bar product liability claims when the cleared device proves defective in clinical use. The ruling substantially supports plaintiffs heading into bellwether trials.

Eligibility framework

The framework for filing PowerPort cases:

Documented PowerPort implantation. Records showing the claimant received a Bard PowerPort or similar Bard port catheter:

• Operative report from implantation surgery
• Implant card or device identification
• Hospital records identifying the specific Bard product
• Surgeon records

Qualifying injury. Documented complications including:

• Catheter fracture (with or without fragment migration)
• Fragment migration requiring surgical retrieval
• Bloodstream infection or sepsis
• Deep vein thrombosis or pulmonary embolism related to device
• Vascular injury
• Need for emergency removal or surgical intervention

Temporal relationship. The injury developed during or after PowerPort use. Cases with strong temporal connection between device implantation and injury are typically stronger than cases with substantial time gaps and multiple alternative explanations.

Documentation requirements:

• Original implantation operative report
• Subsequent medical records showing complications
• Imaging studies showing fracture, migration, or other device problems
• Surgical removal records
• Treatment records for complications (infection treatment, anticoagulation, etc.)
• Pathology reports for retrieved fragments

Statute of limitations analysis. State-specific limitations periods apply. Most states have 2-3 years from injury or discovery. The discovery rule applies in many jurisdictions — limitations begins when the patient knew or should have known about device failure, not at implantation. Cases involving recent complications often qualify for discovery rule extension even when the original device was implanted years ago.

Fibrin encapsulation challenge. Long-implanted devices often develop fibrin encapsulation around the catheter. The encapsulation can:

• Hide signs of catheter fracture from imaging
• Complicate forensic evidence during removal
• Delay diagnosis of device failure
• Affect statute of limitations analysis (discovery rule application)

The encapsulation issue makes documentation particularly important — fragment retrieval and pathology examination can establish device failure even when the encapsulation made detection difficult.

Settlement projections

Settlement values vary substantially by injury type:

Infection-only cases. Tens of thousands of dollars typical, depending on:

• Severity of infection
• Treatment required
• Duration of complications
• Permanent consequences

Fracture cases with migration and vascular injury. Hundreds of thousands of dollars typical:

• Surgical retrieval required
• Hospitalization for complications
• Lost wages
• Pain and suffering

Severe cases. May substantially exceed typical ranges:

• Multiple complications
• Permanent disability
• Wrongful death claims for deceased plaintiffs
• Specific factual circumstances strengthening cases

Bellwether-dependent. Final settlement framework depends substantially on bellwether outcomes through 2026-2027. Strong plaintiff verdicts could accelerate global settlement and increase settlement values. Defense verdicts could reduce settlement leverage.

Becton Dickinson's substantial capacity. BD has substantial financial capacity for settlement (similar to Bard hernia mesh MDL 2846 where BD's multi-billion dollar settlement framework resolved approximately 38,000 claims). The corporate structure suggests resolution capacity exists for substantial settlement.

Tax implications for settlement recipients. Personal injury settlements for physical injuries are generally tax-free under IRC §104(a)(2). But specific components (punitive damages, interest, certain emotional distress damages without physical injury) may be taxable. Coordination with tax counsel before accepting substantial settlements is appropriate — particularly when tax debt forgiveness or other tax issues are involved.

How PowerPort compares to other ongoing mass torts

The litigation has distinctive features:

Compared to Bard hernia mesh MDL 2846 with $1+ billion settlement: Same manufacturer (Bard/BD) facing different product liability theory. Bard hernia mesh reached global settlement through bellwether trials and state court verdicts. PowerPort is in earlier bellwether phase but may follow similar trajectory.

Compared to Exactech device recall MDL 3044 affected by bankruptcy: Both involve medical device manufacturers. Exactech's bankruptcy froze litigation; PowerPort's defendants (BD with substantial financial capacity) face standard MDL framework.

Compared to Philips CPAP MDL 3014 with $1.1 billion settlement: Both involve medical device manufacturers with FDA-related defense issues. Philips reached settlement relatively quickly; PowerPort is in bellwether phase.

Compared to 3M Combat Arms earplugs MDL 2885 with $6 billion settlement: 3M reached settlement after substantial bellwether activity. PowerPort may follow similar timeline through bellwether outcomes.

Compared to NEC infant formula MDL 3026 with substantial state court verdicts: Both involve medical product liability with summary judgment battles. NEC has substantial state court success; PowerPort's federal MDL appears strong heading into bellwethers.

Compared to Ozempic GLP-1 MDL 3094 in earlier phase: PowerPort is procedurally further along with bellwether trials beginning. GLP-1 hasn't reached bellwether selection completion.

The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. PowerPort represents an active, growing mass tort with substantial bellwether trial activity that will determine ultimate resolution framework.

Strategic considerations

For affected patients and prospective plaintiffs:

File claims promptly. Statute of limitations periods are running. The discovery rule provides some flexibility, but cases involving older implantations and recent symptoms benefit from prompt evaluation. Most states have 2-3 year limitations periods from injury or discovery.

Engage experienced mass tort counsel. The MDL is procedurally specific and benefits from counsel with established PowerPort case experience. Most plaintiffs' firms work on contingency basis (typically 30-40% of recovery). Search PACER for plaintiff's counsel experience in the litigation if researching attorneys.

Document the medical timeline comprehensively. The strongest cases include:

• Original PowerPort implantation operative report
• Device identification (specific model, lot number when available)
• Complete medical records following implantation
• Documentation of complications and their development
• Imaging studies showing fracture or migration
• Surgical removal records
• Pathology reports for retrieved fragments
• Continuing treatment records

Watch the bellwether trial outcomes. The six bellwether trials through early 2027 will substantially affect settlement framework. Monitor outcomes through legal news sources or counsel updates. Trial outcomes affect both case-specific viability and overall settlement leverage.

Address fibrin encapsulation documentation carefully. When device is removed, pathology examination of retrieved components is important for establishing fracture or material degradation. Coordinate with treating physicians about preserving evidence during device removal.

Don't accept inadequate pre-bellwether settlements. Some firms may offer early settlements before bellwether outcomes substantially affect pricing. Have any settlement offer evaluated by counsel familiar with current litigation dynamics. Early settlements typically don't include the full value that bellwether-supported settlements provide.

Plan for extended timeline. Bellwether trials continuing through early 2027. Global settlement (if reached) likely 2027-2029. Plan for extended timeline rather than expecting near-term resolution.

Coordinate with treating physicians. Oncologists, infectious disease specialists, vascular surgeons, and other treating physicians are important witnesses. Their support for the case theory and connection to PowerPort device strengthens cases substantially.

Consider wrongful death framework for deceased plaintiffs. Estates of deceased plaintiffs (including those who died during the litigation like second bellwether plaintiff Wanda Miller) can pursue wrongful death claims with separate procedural framework.

Tax planning for substantial settlements. Settlement allocation between physical injury (tax-free under §104(a)(2)) and other components (potentially taxable) requires careful structuring. Coordinate with tax counsel familiar with personal injury settlement structuring — particularly when other tax issues like NFTL withdrawals or Voluntary Disclosure Practice considerations exist.

Watch for state court alternatives. Some plaintiffs may benefit from state court filings rather than federal MDL participation. The procedural analysis depends on state-specific factors and case characteristics.

Cancer patient considerations. PowerPort plaintiffs often have ongoing oncological treatment needs. Coordinate medical care with legal pursuit — don't let case management interfere with active cancer treatment. Legal counsel familiar with cancer patient situations handles these cases more sensitively.

The Bard PowerPort litigation represents a mass tort with strong substantive case theory, substantial procedural momentum heading into bellwether trials, and a financially-capable defendant that can fund eventual global settlement. The combination of Judge Campbell's denial of Bard's summary judgment motions, the active bellwether trial schedule running through early 2027, and the cancer patient demographic creates conditions for meaningful resolution within the next 2-4 years. The substantive case theory — that polyurethane-barium sulfate composition causes catheter fracture and migration — has survived motion practice and is now being tested before juries. For affected patients with documented PowerPort complications, the framework provides paths to compensation that recognize the serious harm caused by device failures in already-vulnerable cancer patient populations. The work for plaintiffs is in comprehensive medical documentation, engagement with experienced counsel familiar with the MDL framework, patient navigation of the extended bellwether timeline, and informed evaluation of settlement opportunities as bellwether outcomes affect the settlement landscape. For plaintiffs with strong documentation and serious injuries, the eventual resolution should produce meaningful compensation for medical costs, lost wages, pain and suffering, and the quality of life impact caused by the alleged catheter defects.